Search - tctmd.com

Displaying 241 - 260 of 399

Sort: Relevancy | Date

News Conference News ESC 2019

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Shelley Wood

September 03, 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Published Cohort

News Conference News ESC 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Yael L. Maxwell

September 03, 2019

News Conference News ESC 2019

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Michael O'Riordan

September 02, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Daily News

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

Michael O'Riordan

August 21, 2019

News Daily News

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Yael L. Maxwell

August 14, 2019

News Daily News

Nonobstructive CAD on Cardiac CTA a Golden Opportunity to Boost Statin Prescribing

Michael O'Riordan

July 22, 2019

News Daily News

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Michael O'Riordan

July 19, 2019

News Daily News

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Michael O'Riordan

July 01, 2019

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

News Conference News EAS 2019

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

Michael O'Riordan

June 03, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Daily News

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

Michael O'Riordan

May 15, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

Yael L. Maxwell

April 24, 2019

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

L.A. McKeown

April 03, 2019

News Daily News

Many Statin-Eligible Patients Don’t Take Meds, and Say Doctor Is to Blame

Michael O'Riordan

March 27, 2019

Advertisement

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Nonobstructive CAD on Cardiac CTA a Golden Opportunity to Boost Statin Prescribing

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

CHD Mortality Significantly Elevated in Patients With Severe FH

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

Many Statin-Eligible Patients Don’t Take Meds, and Say Doctor Is to Blame

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content